机构持仓方面，截止2025年6月30日，华润三九十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4361.40万股，相比上期增加705.16万股。华泰柏瑞沪深300ETF（510300）位居第四大流 通股东，持股1193.47万股，相比上期增加356.72万股。易方达沪深300医药ETF（512010）位居第五大 流通股东，持股1096.93万股，相比上期增加185.89万股。易方达沪深300ETF（510310）位居第七大流 通股东，持股848.71万股，相比上期增加261.73万股。中欧医疗健康混合A（003095）退出十大流通股 东之列。 华润三九所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：维生素、禽流感药物、医药 电商、抗流感、化妆品等。 截至9月20日，华润三九股东户数10.04万，较上期增加6.25%；人均流通股16561股，较上期减少 5.88%。2025年1月-6月，华润三九实现营业收入148.10亿元，同比增长4.99%；归母净利润18.15亿元， 同比减少24.31%。 分红方面，华润三九A股上市后累计派现100.69亿元。近三年，累计派现49.15亿元。 1 ...

10月9日，以岭药业盘中上涨2.01%，截至13:31，报16.21元/股，成交2.03亿元，换手率0.92%，总市值 270.82亿元。 以岭药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：创新药、抗癌药物、抗癌治 癌、中药、幽门螺杆概念等。 截至6月30日，以岭药业股东户数17.01万，较上期减少8.18%；人均流通股8093股，较上期增加8.91%。 2025年1月-6月，以岭药业实现营业收入40.40亿元，同比减少12.26%；归母净利润6.69亿元，同比增长 26.03%。 分红方面，以岭药业A股上市后累计派现39.54亿元。近三年，累计派现13.37亿元。 机构持仓方面，截止2025年6月30日，以岭药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1759.21万股，相比上期减少567.82万股。南方中证500ETF（510500）位居第五大流通股 东，持股1239.65万股，相比上期增加176.50万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股384.98万股，相比上期减少43.25万股。 责任编辑：小浪快报 资金流向方面，主力资金净流入5 ...

资金流向方面，主力资金净流入1516.41万元，特大单买入1892.06万元，占比16.07%，卖出119.71万 元，占比1.02%；大单买入2560.02万元，占比21.75%，卖出2815.97万元，占比23.92%。 马应龙今年以来股价涨5.85%，近5个交易日涨0.37%，近20日涨1.24%，近60日涨0.33%。 资料显示，马应龙药业集团股份有限公司位于湖北省武汉市武昌南湖周家湾100号，成立日期1994年5月 9日，上市日期2004年5月17日，公司主营业务涉及药品制造、医药零售及批发以及医疗服务等。主营业 务收入构成为：治痔类45.53%，零售、批发34.93%，其他16.43%，医院诊疗3.11%。 马应龙所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：基因测序、医药电商、中药、 化妆品、民营医院等。 10月9日，马应龙盘中上涨2.00%，截至11:20，报26.98元/股，成交1.18亿元，换手率1.02%，总市值 116.30亿元。 截至6月30日，马应龙股东户数3.11万，较上期减少23.07%；人均流通股13825股，较上期增加29.98%。 2025年1月-6月，马应 ...

10月9日，吉林敖东盘中上涨2.15%，截至10:58，报20.44元/股，成交2.92亿元，换手率1.23%，总市值 244.44亿元。 资金流向方面，主力资金净流入823.28万元，特大单买入1466.16万元，占比5.02%，卖出1931.71万元， 占比6.62%；大单买入7803.29万元，占比26.73%，卖出6514.46万元，占比22.31%。 吉林敖东今年以来股价涨20.41%，近5个交易日涨7.07%，近20日涨7.07%，近60日涨19.88%。 分红方面，吉林敖东A股上市后累计派现44.30亿元。近三年，累计派现16.47亿元。 机构持仓方面，截止2025年6月30日，吉林敖东十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1501.38万股，相比上期增加461.49万股。南方中证500ETF（510500）位居第五大流通股 东，持股1424.79万股，相比上期增加191.48万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股440.92万股，相比上期减少48.30万股。 责任编辑：小浪快报 资料显示，吉林敖东药业集团股份有限公司位于吉林省敦化市敖东大街 ...

Core Viewpoint - Fangsheng Pharmaceutical has shown a positive stock performance with a year-to-date increase of 20.68% and a recent surge of 12.06% over the past five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2]. - The top ten circulating shareholders include notable institutional investors, with ICBC Medical Health Stock holding 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed Fund increasing its holdings by 500,000 shares to 5 million [3]. Market Activity - On September 26, Fangsheng Pharmaceutical's stock price rose by 2.11% to 12.08 yuan per share, with a trading volume of 125 million yuan and a turnover rate of 2.42%, resulting in a total market capitalization of 5.304 billion yuan [1]. - The net inflow of main funds was 4.67 million yuan, with significant buying activity from large orders, indicating strong investor interest [1].

Company Overview - JiuZhiTang has seen a stock price increase of 32.19% year-to-date, but has experienced a slight decline of 0.30% over the last 5 trading days and a more significant drop of 11.53% over the last 20 days [2] - The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs, with its main revenue sources being prescription drugs (50.27%) and OTC products (46.11%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported a revenue of 1.265 billion yuan, representing a year-on-year decrease of 24.71%, while the net profit attributable to shareholders was 144 million yuan, down 29.71% year-on-year [3] - Cumulative cash dividends since the company's A-share listing amount to 4.364 billion yuan, with 935 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 50,500, marking a 25.14% rise, while the average number of circulating shares per person decreased by 20.09% to 13,739 shares [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Market Activity - On September 26, JiuZhiTang's stock rose by 2.12%, reaching 10.13 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 1.62% [1] - The net inflow of main funds was 593,400 yuan, with significant buying and selling activity recorded [1]

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]

Core Viewpoint - Wanbangde's stock price has shown significant volatility, with a year-to-date increase of 71.38% but a recent decline of 4.09% over the last five trading days [2] Group 1: Stock Performance - As of September 25, Wanbangde's stock price was 11.02 CNY per share, with a market capitalization of 6.741 billion CNY [1] - The stock has experienced a 17.36% increase over the past 20 days and a 57.65% increase over the past 60 days [2] - The company has appeared on the "龙虎榜" (top trading list) five times this year, with the most recent occurrence on August 27 [2] Group 2: Financial Performance - For the first half of 2025, Wanbangde reported revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company's main business revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] Group 3: Shareholder Information - As of June 30, the number of shareholders for Wanbangde was 39,300, an increase of 42.08% from the previous period, while the average circulating shares per person decreased by 30.25% to 14,085 shares [2] Group 4: Dividend Information - Since its A-share listing, Wanbangde has distributed a total of 613 million CNY in dividends, with 122 million CNY distributed over the past three years [3]

9月24日，陇神戎发盘中上涨2.10%，截至13:38，报9.71元/股，成交4516.86万元，换手率1.55%，总市 值29.45亿元。 资金流向方面，主力资金净流入156.88万元，特大单买入100.63万元，占比2.23%，卖出0.00元，占比 0.00%；大单买入842.75万元，占比18.66%，卖出786.50万元，占比17.41%。 陇神戎发所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：甘肃国资、医药电商、中 药、小盘、医疗器械等。 截至9月10日，陇神戎发股东户数2.78万，较上期减少0.71%；人均流通股10853股，较上期增加0.71%。 2025年1月-6月，陇神戎发实现营业收入4.96亿元，同比减少9.91%；归母净利润2795.61万元，同比增长 30.31%。 分红方面，陇神戎发A股上市后累计派现4264.16万元。近三年，累计派现2426.76万元。 机构持仓方面，截止2025年6月30日，陇神戎发十大流通股东中，汇添富中证中药ETF（560080）位居 第六大流通股东，持股97.85万股，相比上期减少10.16万股。 责任编辑：小浪快报 陇神戎发今年以来股价涨1 ...

佐力药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：基因测序、医药电商、中 药、生物医药、创新药等。 9月24日，佐力药业盘中上涨2.05%，截至10:16，报17.92元/股，成交8322.21万元，换手率0.78%，总市 值125.69亿元。 资金流向方面，主力资金净流入1198.85万元，特大单买入0.00元，占比0.00%，卖出106.94万元，占比 1.28%；大单买入2414.17万元，占比29.01%，卖出1108.38万元，占比13.32%。 佐力药业今年以来股价涨21.34%，近5个交易日跌0.78%，近20日跌6.42%，近60日涨2.40%。 资料显示，浙江佐力药业股份有限公司位于浙江省德清县阜溪街道志远北路388号，成立日期2000年1月 28日，上市日期2011年2月22日，公司主营业务涉及药用真菌乌灵系列和百令片产品、中药饮片及中药 配方颗粒的研发、生产与销售。主营业务收入构成为：乌灵系列56.07%，中药饮片系列21.85%，其他 产品10.11%，百令系列7.08%，中药配方颗粒4.62%，其他(补充)0.26%。 责任编辑：小浪快报 截至6月30日，佐力药业股 ...